Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance
R Ge, Z Wang, L Cheng - NPJ precision oncology, 2022 - nature.com
Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …
challenge to precision therapy and drug development. In this review, we discuss how …
BRCA1-Dependent and independent recruitment of PALB2–BRCA2–RAD51 in the DNA damage response and Cancer
Abstract The BRCA1–PALB2–BRCA2 axis plays essential roles in the cellular response to
DNA double-strand breaks (DSB), maintenance of genome integrity, and suppression of …
DNA double-strand breaks (DSB), maintenance of genome integrity, and suppression of …
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
To understand the mechanism of acquired resistance to poly (ADP-ribose) polymerase
inhibitors (PARPi) olaparib, we induced the formation of polyploid giant cancer cells …
inhibitors (PARPi) olaparib, we induced the formation of polyploid giant cancer cells …
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
C Stossel, M Raitses-Gurevich, D Atias, T Beller… - Cancer discovery, 2023 - AACR
Germline BRCA–associated pancreatic ductal adenocarcinoma (gl BRCA PDAC) tumors are
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
B Pellegrino, A Herencia-Ropero, A Llop-Guevara… - Cancer research, 2022 - AACR
PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous
ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring …
ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring …
[HTML][HTML] Mechanism of PARP inhibitor resistance and potential overcoming strategies
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose)
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …
CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair
A critical determinant of DNA repair pathway choice is REV7, an adaptor that binds to
various DNA repair proteins through its C-terminal seatbelt domain. The REV7 seatbelt …
various DNA repair proteins through its C-terminal seatbelt domain. The REV7 seatbelt …
The proofreading exonuclease of leading-strand DNA polymerase epsilon prevents replication fork collapse at broken template strands
T Ahmad, R Kawasumi, T Taniguchi, T Abe… - Nucleic Acids …, 2023 - academic.oup.com
Leading-strand DNA replication by polymerase epsilon (Polϵ) across single-strand breaks
(SSBs) causes single-ended double-strand breaks (seDSBs), which are repaired via …
(SSBs) causes single-ended double-strand breaks (seDSBs), which are repaired via …
[HTML][HTML] The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
S Bouberhan, L Bar-Peled, Y Matoba… - Cancer Drug …, 2023 - ncbi.nlm.nih.gov
Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and
taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase …
taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase …
Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer
YN Kim, Y Shim, J Seo, Z Choi, YJ Lee, S Shin… - Clinical Cancer …, 2023 - AACR
Purpose: Patient-specific molecular alterations leading to poly ADP-ribose polymerase
inhibitor (PARPi) resistance are relatively unexplored. In this study, we analyzed serially …
inhibitor (PARPi) resistance are relatively unexplored. In this study, we analyzed serially …